Development of a human thymic organ culture model for the study of HIV pathogenesis.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Development of a human thymic organ culture model for the study of HIV pathogenesis.

AIDS Res Hum Retroviruses. 1995 Sep;11(9):1073-80. Unique Identifier : AIDSLINE MED/96089214
Bonyhadi ML; Su L; Auten J; McCune JM; Kaneshima H; HIV Group, SyStemix, Inc., Palo Alto, California 94304, USA.

Abstract: The development of effective therapies for the treatment of AIDS would be facilitated by a better understanding of HIV pathogenesis in vivo. While some aspects of pathogenesis may be assessed by standard tissue culture assays, in vivo animal models may provide clues to other aspects of HIV-mediated progression toward AIDS. Current animal models include primate models for the study of simian immunodeficiency virus (SIV) and HIV, SCID-hu and hu-PBL SCID mouse models for the study of HIV, and feline models for the study of feline immunodeficiency virus (FIV). In general these models are costly and labor intensive. We have developed a simple human fetal thymic organ culture (TOC) system that is permissive for HIV infection and that exhibits pathology similar to that observed in vivo. A key feature of this system is the time-dependent destruction of thymocytes typified by the preferential loss of CD4-expressing cells. HIV-mediated thymocyte destruction occurs by a process involving programmed cell death. We have infected TOC with a panel of HIV isolates and found that the resulting viral replicative and pathogenic profiles are similar to those seen in the SCID-hu Thy/Liv mouse, yet different from profiles observed in standard PHA-blast tissue culture assays. In addition, we find that TOC may be used to assess efficacy of antiviral agents such as AZT (3'-azido-3'-deoxythymidine) and ddI (2',3'-dideoxyinosine) in blocking both viral replication and virus-induced pathology. These results indicate that this model is amenable to the systematic manipulation, analysis, and characterization of a variety of HIV virus isolates and antiviral therapies.

Keywords: Animal Antiviral Agents/PHARMACOLOGY Apoptosis Cats Comparative Study CD4-CD8 Ratio CD4-Positive T-Lymphocytes/IMMUNOLOGY/PATHOLOGY Didanosine/PHARMACOLOGY Drug Screening/METHODS Fetus Human HIV Infections/DRUG THERAPY/*ETIOLOGY/IMMUNOLOGY HIV-1/DRUG EFFECTS/PHYSIOLOGY/*PATHOGENICITY Mice *Models, Biological Organ Culture/METHODS/STANDARDS Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Thymus Gland/IMMUNOLOGY/PATHOLOGY/*VIROLOGY Time Factors Virus Replication Zidovudine/PHARMACOLOGY JOURNAL ARTICLE
960530
M9651092

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .